Patient Treatment Completed in Phase 1/2 Trial Testing Therapy Candidate CDNF in Parkinson’s Disease

Patient Treatment Completed in Phase 1/2 Trial Testing Therapy Candidate CDNF in Parkinson’s Disease
Patient treatment has been completed in a Phase 1/2 clinical trial testing cerebral dopamine neurotrophic factor (CDNF) for Parkinson’s disease, Herantis Pharma has announced. The trial (NCT03295786) is testing the safety and tolerability of CDNF in 17 patients with advanced Parkinson’s disease. Of these patients, 15 completed the main study and will advance into a six-month extension study where they ... read more
Source: Parkinson’s News TodayPublished on 2020-01-03By Patricia Inacio, PhD